Nuvation Bio

Today we reported third quarter 2024 financial results and provided a business update. See more: https://bit.ly/48LyUEP #oncology #cancer #biotech 

As we launch wellness month here at Nuvation Bio, we believe it’s important to support our colleagues’ wellbeing, which is why we are excited for our 2nd Annual NUV on the Move initiative! This year we are proud to partner with The Leukemia & Lymphoma Society via Charity Miles to support a mission that’s close to our hearts. Learn about more ways our team is making an impact: https://shorturl.at/hkOFl

Please join us in welcoming Philippe Sauvage as our new Chief Financial Officer! Philippe brings over 20 years of global finance, operations, and commercialization experience across leading #healthcare and #biopharma companies that have made a difference for patients. He will be integral as we advance our mission to tackle some of the greatest unmet needs in #oncology. Read the announcement: https://lnkd.in/e3Q8f7pc

Today, on #WorldCancerResearchDay, we stand united in our mission to advance new possibilities in #cancer research and treatment. At Nuvation Bio, we are dedicated to developing our pipeline programs in #solidtumors – taletrectinib, safusidenib, NUV-1511, and NUV-868 – to change the lives of people with difficult-to-treat cancers. Learn more: https://rb.gy/kdfarb

Our team recently participated in a back-to-school backpack drive with Family Giving Tree. We were proud to come together to help give children the supplies they need to start the school year off right! Learn more about the great work Family Giving Tree is doing: https://lnkd.in/g-JdFJA

Today at #ESMO24, we shared pooled data from our pivotal studies, TRUST-I and TRUST-II, showcasing the potential for our #ROS1 inhibitor in #NSCLC. We look forward to our planned NDA submission in the fourth quarter of 2024 based on these data. Learn more: https://bit.ly/3Xu0G3o

Don’t miss Nuvation’s presentation at the Cantor Fitzgerald Global Healthcare Conference next Thursday, where management will highlight exciting data updates and next steps for our lead #ROS1 inhibitor for #NSCLC, and progress across the rest of our #oncology pipeline. Get details here: https://lnkd.in/eXdAcGDE

We’re excited to connect with the #lungcancer and #oncology communities at next week’s #WCLC24 and #ESMO24. If you’re attending, don’t miss our presentations, where we'll be sharing new, positive data on our investigational #ROS1 inhibitor for #NSCLC. Details below.

We recently had the privilege of meeting with members of The ROS1ders community to better understand their journeys with #ROS1 positive #cancers, including #NSCLC. The stories and insights had a profound impact on us, reinforcing our commitment to advancing treatment options and improving patient outcomes. Swipe through to see our key takeaways. 👇

We are thrilled to join The ROS1ders’ PRIME Summit starting tomorrow! We look forward to connecting with patients, caregivers and advocates impacted by #ROS1 positive #cancers and supporting the event as a platinum sponsor. Learn more about how this organization works to improve outcomes for all ROS1-positive cancers through community, education and research: https://lnkd.in/ee39X9Gi #oncology #NSCLC #lungcancer